Nav: Home

Analysis: Survival benefit for African-Americans with advanced prostate cancer

June 01, 2018

DURHAM, N.C. -- Contrary to current perceptions, certain African-American men with advanced prostate cancer have as good a chance of survival as white men and might actually have a small advantage, according to a new analysis of more than 8,000 patients who participated in clinical trials.

In a study presented June 1 at the American Society of Clinical Oncology, lead author Susan Halabi, Ph.D., professor of biostatistics and member of the Duke Cancer Institute, said the racial disparities long associated with prostate cancer are complex and persistent. But for men with advanced disease who are treated with a common chemotherapy drug along with steroids, the risk of death is actually lower for African-Americans.

"When we looked at the raw, median survival for white and African-American men in our study, it was equal, at about 21 months," Halabi said. "But when you compare the men based on similar characteristics that influence survival, the African-American men actually had a 19 percent lower risk for death than white men."

Halabi and colleagues conducted their analysis on pooled data from nine large studies that used the chemotherapy drug docetaxel, which is a standard therapy and is typically taken along with the steroid prednisone.

Of the more than 8,000 men included in the analysis, 500 were African-American -- a large cohort despite low enrollments of African-American men for each of the individual studies. They then took into consideration patient characteristics already known to affect survival in the analysis, including age, performance status such as ability to manage daily activities, prostate-specific antigen (PSA) levels, site of metastases and other factors.

African-American men in the analysis were younger and sicker than the white men, as measured by the key survival factors. Despite that, the overall median survival for African-American men was nearly equal to the white men at 21 months.

That alone was unexpected, Halabi said, since the African-American men carried a heavier burden of disease. But when they compared men of different races to each other based on the key disease variables, the survival advantage for African-Americans was even more surprising.

"These findings are specific to men who enrolled in these trials and who have been treated with docetaxel-based therapies. The results of this analysis suggest there might be biological variations in either the disease or response to treatments that should be further explored," Halabi said.
-end-
The study received funding from the Congressionally Directed Medical Research Programs.

In addition to Halabi, study authors included Sandipan Dutta, Catherine M. Tangen, Mark Rosenthal, Daniel Peter Petrylak, Ian Murchie Thompson Jr., Kim N. Chi, Johann S. De Bono, Abderrahim Fandi, John C. Araujo, Mario A. Eisenberger, Christopher Logothetis, David I. Quinn, Karim Fizazi, Celestia S. Higano, Daniel J. George, Michael J. Morris, Eric Jay Small, Ian Tannock, and William Kevin Kelly.

Duke University Medical Center

Related Prostate Cancer Articles:

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
More Prostate Cancer News and Prostate Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Our Relationship With Water
We need water to live. But with rising seas and so many lacking clean water – water is in crisis and so are we. This hour, TED speakers explore ideas around restoring our relationship with water. Guests on the show include legal scholar Kelsey Leonard, artist LaToya Ruby Frazier, and community organizer Colette Pichon Battle.
Now Playing: Science for the People

#569 Facing Fear
What do you fear? I mean really fear? Well, ok, maybe right now that's tough. We're living in a new age and definition of fear. But what do we do about it? Eva Holland has faced her fears, including trauma and phobia. She lived to tell the tale and write a book: "Nerve: Adventures in the Science of Fear".
Now Playing: Radiolab

Uncounted
First things first: our very own Latif Nasser has an exciting new show on Netflix. He talks to Jad about the hidden forces of the world that connect us all. Then, with an eye on the upcoming election, we take a look back: at two pieces from More Perfect Season 3 about Constitutional amendments that determine who gets to vote. Former Radiolab producer Julia Longoria takes us to Washington, D.C. The capital is at the heart of our democracy, but it's not a state, and it wasn't until the 23rd Amendment that its people got the right to vote for president. But that still left DC without full representation in Congress; D.C. sends a "non-voting delegate" to the House. Julia profiles that delegate, Congresswoman Eleanor Holmes Norton, and her unique approach to fighting for power in a virtually powerless role. Second, Radiolab producer Sarah Qari looks at a current fight to lower the US voting age to 16 that harkens back to the fight for the 26th Amendment in the 1960s. Eighteen-year-olds at the time argued that if they were old enough to be drafted to fight in the War, they were old enough to have a voice in our democracy. But what about today, when even younger Americans are finding themselves at the center of national political debates? Does it mean we should lower the voting age even further? This episode was reported and produced by Julia Longoria and Sarah Qari. Check out Latif Nasser's new Netflix show Connected here. Support Radiolab today at Radiolab.org/donate.